Absci is trading at $11.64, up 10.12%, with biotech-sector strength a possible tailwind. - The XBI rose 2.18% during the regular session amid positive clinical and regulatory news across the industry. - No clear new Absci-specific catalyst was identified for October 28; the company’s October 27 announcement concerned investor-conference participation.